Stockholm, Sweden

Sylvia Simon

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Sylvia Simon: Innovator in Amyloid Beta Research

Introduction

Sylvia Simon is a prominent inventor based in Stockholm, Sweden. She has made significant contributions to the field of biomedical research, particularly in the development of antibodies targeting amyloid beta peptides. With a total of 5 patents to her name, her work is crucial in addressing conditions associated with amyloidosis, including Alzheimer's disease.

Latest Patents

Among her latest patents, Sylvia has developed antibodies that selectively bind to human amyloid beta 42 peptide over human amyloid beta 40 peptide. These antibodies are designed as therapeutic agents for binding amyloid beta 42 peptide, which is essential in treating conditions related to amyloidosis. Her innovative approach aims to provide new avenues for the treatment of Alzheimer's disease, showcasing her commitment to advancing medical science.

Career Highlights

Sylvia Simon is currently associated with Medimmune Limited, where she continues her groundbreaking research. Her work has not only contributed to the scientific community but has also paved the way for potential therapeutic solutions for patients suffering from neurodegenerative diseases.

Collaborations

Sylvia collaborates with talented professionals in her field, including Maria Groves and Suzanne Gustavsson. These partnerships enhance her research efforts and contribute to the overall success of her projects.

Conclusion

Sylvia Simon's innovative work in the development of antibodies for amyloid beta peptides positions her as a key figure in the fight against Alzheimer's disease. Her contributions are vital for advancing therapeutic strategies and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…